A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial data versus Ravulizumab and Eculizumab in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (EHA 2022) - Apellis Medical Hub

A Matching-Adjusted Indirect Comparison of the Efficacy of Pegcetacoplan using PRINCE Trial data versus Ravulizumab and Eculizumab in Complement-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Share Via Email

Back to Conference Resources

PNH Congress Presentations European Hematology Association (EHA) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.